Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The c-MYC promoter nuclease hypersensitive element III1 (NHEIII1) G-quadruplex is a non-canonical DNA secondary structure located approximately 115 to 142 base pairs upstream of the P1 promoter of the c-MYC oncogene (Siddiqui-Jain et al., 2002). This region contains a guanine-rich sequence that can fold into a four-stranded structure stabilized by Hoogsteen hydrogen bonds, which serves as a molecular switch for gene expression (Brooks & Hurley, 2010). In its folded G-quadruplex state, it physically obstructs the transcriptional machinery, thereby repressing the transcription of c-MYC, a master regulator of cell proliferation and metabolism (Balasubramanian et al., 2011). Because c-MYC is constitutively overexpressed in a vast majority of human cancers, this G-quadruplex is a high-value target for small-molecule intervention (Ou et al., 2008). Therapeutic strategies focus on using small-molecule ligands to stabilize the G-quadruplex, effectively silencing the oncogene and inducing growth arrest or apoptosis in malignant cells (Hurley et al., 2006). However, the primary challenge in targeting this structure is achieving sufficient selectivity to avoid interfering with other essential G-quadruplexes found in telomeres or other gene promoters (Balasubramanian et al., 2011).
Stabilization of the G-quadruplex structure within the NHEIII1 region of the c-MYC promoter to sterically inhibit the binding of transcription factors and RNA polymerase, leading to the downregulation of c-MYC oncogene expression.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on c-MYC promoter nuclease hypersensitive element III1 G-quadruplex (c-MYC NHEIII1 G4) (c-MYC NHEIII1 G4).